nach oben

Current Hepatology Reports

Erschienen in:

06.04.2018 | Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures

verfasst von: Mark Pederson, Marlyn J. Mayo

Erschienen in: Current Hepatology Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Pruritus in cholestatic liver disease is commonly encountered and difficult to eradicate. It has a major impact on quality of life and thus is important to address. This article reviews current and future treatment options for cholestatic pruritus.

Recent Findings

In the last 5 years, the pathogenesis of cholestatic itch has been further clarified via studies of serum autotaxin, which correlates with severity of symptoms and decrease in patients on therapy. New medications under development include apical sodium-dependent bile acid transporters (maralixibat, GSK2330672), fibrates (bezafibrate), and κ-opioid receptor agonists (nalfurafine hydrochloride).

Summary

While many treatments are available to treat this vexing condition, data to support consistent and dramatic improvement with any one medication is lacking. However, with so many options and several new medications under investigation in clinical trials, symptom relief is an achievable goal for many patients.

Lawley T, Yancey K. Approach to the patient with a skin disorder. In: Kasper D, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. In Fauci A BE. Harrison’s Principles of Internal Medicine USA: The McGraw-Hil Companies; 2008. p. 308–12.

Jin X, Khan T. Quality of life among patients suffering from cholestatic liver disease-induced pruritus: a systematic review. J Formos Med Assoc. 2016;115:689–702.CrossRefPubMed

Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, Kalaitzakis E. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10(7):769–75 e2. https://doi.org/10.1016/j.cgh.2012.01.025.CrossRefPubMed

Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120(1):170–8. https://doi.org/10.1053/gast.2001.21193.CrossRefPubMed

Poupon RE, Chretien Y, Chazouilleres O, Poupon R, Chwalow J. Quality of life in patients with primary biliary cirrhosis. Hepatology. 2004;40(2):489–94. https://doi.org/10.1002/hep.20276.CrossRefPubMed

Stanca CM, Bach N, Krause C, Tandon N, Freni MA, Gutierrez JA, et al. Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol. 2005;100(5):1104–9. https://doi.org/10.1111/j.1572-0241.2005.41315.x.CrossRefPubMed

Younossi Y, Kiwi M, Boparai N, Price L, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol. 2000;95:497–502.CrossRefPubMed

Lens S, Leoz M, Nazal L, Bruguera M, Pares A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34(2):197–203. https://doi.org/10.1111/liv.12290.CrossRefPubMed

•• Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43. https://doi.org/10.1056/NEJMoa1509840. A phase 3 study demonstrating the efficacy of obeticholic acid for the treatment of PBC experiencing suboptimal response to UDCA. CrossRefPubMed

10.

•• Reig A, Sese P, Pares A. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol. 2018;113(1):49–55. https://doi.org/10.1038/ajg.2017.287. A trial of 48 patients demonstrating the beneficial effects of long-term bezafibrate effects in patients with PBC experiencing suboptimal response to UDCA. CrossRefPubMed

11.

Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with alagille syndrome: the King's College Hospital experience. J Pediatr Gastroenterol Nutr. 2013;57(2):149–54. https://doi.org/10.1097/MPG.0b013e318297e384.CrossRefPubMed

12.

Rishe E, Azarm A, Bergasa N. Itch in primary biliary cirrhosis: a patients’ perspective. Acta Derm Venereol. 2008;88:34–7.CrossRefPubMed

13.

Alighieri D. Inferno. New York: Race Point Publishing; 2015.

14.

Peddicord S. FDA approves Ocaliva for rare, chronic liver disease. 2016.

15.

•• Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–61 e8. https://doi.org/10.1053/j.gastro.2014.12.005. A phase 3 study demonstrating the efficacy of obeticholic acid for the treatment of PBC experiencing suboptimal response to UDCA. CrossRefPubMed

16.

Mason A, Luketic V, Lindor K, Hirschfield G, Gordon S, Mayo M, et al. 2 Farsenoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol. 2010;52(Suppl):S1–2.CrossRef

17.

Patrick DL, Bush JW, Chen MM. Methods for measuring levels of well-being for a health status index. Helth Serv Res. 1973;8:228–45.

18.

Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y. Visual analogue scale in formats other than a 10 cm horizontal line to assess pain and other clinical data. J Rheumatol. 2008;35(8):1550–8.PubMed

19.

Price DD, Busch FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating. Pain. 1994;56:217–26.CrossRefPubMed

20.

Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497–501. https://doi.org/10.2340/00015555-1265.CrossRefPubMed

21.

Reich A, Riepe C, Anastasiadou Z, Medrek K, Augustin M, Szepietowski JC, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol. 2016;96(7):978–80. https://doi.org/10.2340/00015555-2433.CrossRefPubMed

22.

Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587–93. https://doi.org/10.1111/j.1365-2133.2009.09586.x.CrossRefPubMed

23.

Ward L, Wright E, McMahon SBA. Comparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain. Pain. 1996;64:129–38.CrossRefPubMed

24.

Ochoa J, Torebjork E. Sensations evoked by intraneural microstimulation of C nociceptor fibres in human skin nerves. J Physiol. 1989;415:583–99.CrossRefPubMedPubMedCentral

25.

Schmelz M, Schmidt R, Bickel A, Handwerker H, Torebjork H, Specific C. Receptors for itch in human skin. J Neurosci. 1997;17:8003–8.CrossRefPubMed

26.

Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neuro-Oncol. 2003;89:2441–8.

27.

Patel KN, Dong X. Itch: cells, molecules, and circuits. ACS Chem Neurosci. 2011;2(1):17–25. https://doi.org/10.1021/cn100085g.CrossRefPubMed

28.

• Kremer AE, Feramisco J, Reeh PW, Beuers U, Receptors OERP. Cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta. 2014;1842(7):869–92. https://doi.org/10.1016/j.bbadis.2014.02.007. An excellent review of the molecular mechanisms and neurological pathways involved in cholestatic pruritus. CrossRefPubMed

29.

Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007;448(7154):700–3. https://doi.org/10.1038/nature06029.CrossRefPubMed

30.

Jinks SL, Carstens E. Responses of superficial dorsal horn neurons to intradermal serotonin and other irritants: comparison with scratching behavior. J Neuro-Oncol. 2002;87:1280–9. https://doi.org/10.1152/jn.00431.2001.

31.

Kittaka H, Uchida K, Fukuta N, Tominaga M. Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1. J Physiol. 2017;595(8):2681–98. https://doi.org/10.1113/JP273961.CrossRefPubMedPubMedCentral

32.

Nelson L, Vergnolle N, D'Mello C, Chapman K, Le T, Swain MG. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol. 2006;44(6):1141–9. https://doi.org/10.1016/j.jhep.2005.11.043.CrossRefPubMed

33.

Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013;123(4):1513–30. https://doi.org/10.1172/JCI64551.CrossRefPubMedPubMedCentral

34.

Datta DV, Sherlock S. Cholestyramine for the long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323–32. https://doi.org/10.1016/S0016-5085(66)80071-9. PubMed

35.

Di Padova C, Tritapepe R, Rovagnati P, Rossetti S. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol. 1984;6:773–6.PubMed

36.

Appleby VJ, Hutchinson JM, Davies MH. Safety and efficacy of long-term nasobiliary drainage to treat intractable pruritus in cholestatic liver disease. Frontline Gastroenterol. 2015;6(4):252–4. https://doi.org/10.1136/flgastro-2014-100489.CrossRefPubMed

37.

• Hegade VS, Krawczyk M, Kremer AE, Kuczka J, Gaouar F, Kuiper EM, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther. 2016;43(2):294–302. https://doi.org/10.1111/apt.13449. Evaluated the safety and effectiveness of nasobiliary drainage in 27 patients with refractory cholestatic pruritus. CrossRefPubMed

38.

Freedman MRH, Holzbach RT, Ferguson DR. Pruritus in cholestasis: no direct causative role in bile acid retention. Am J Med. 1981;70(5):1011–6.CrossRefPubMed

39.

Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut. 1972;13:201–6.CrossRefPubMedPubMedCentral

40.

Kremer AE, Martens JJ, Kulik W, Rueff F, Kuiper EM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008–18, 18 e1. https://doi.org/10.1053/j.gastro.2010.05.009.CrossRefPubMed

41.

Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391–400. https://doi.org/10.1002/hep.25748.CrossRefPubMed

42.

Kremer AE, Gonzales E, Schaap FG, Oude Elferink RP, Jacquemin E, Beuers U. Serum Autotaxin activity correlates with pruritus in pediatric cholestatic disorders. J Pediatr Gastroenterol Nutr. 2016;62(4):530–5. https://doi.org/10.1097/MPG.0000000000001044.CrossRefPubMed

43.

Kremer AE, Bolier R, Dixon PH, Geenes V, Chambers J, Tolenaars D, et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol. 2015;62(4):897–904. https://doi.org/10.1016/j.jhep.2014.10.041.CrossRefPubMed

44.

Berstein JE, Switft R. Relief of intractable pruritus with naloxone. Arch Dermatol. 1979;115:1366–7. https://doi.org/10.1001/archderm.1979.04010110058029.CrossRef

45.

Thornton JR, Losowsky MS. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol. 1989;8:53–9.CrossRefPubMed

46.

Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male is associated with naloxone-reversible antinociception. J Hepatol. 1994;20:85–90.CrossRefPubMed

47.

Spivey JR, Jorgensen RA, Gores GJ, Lindor KD. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 1994;89(11):2028–32.PubMed

48.

Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut. 1990;31:96–9.CrossRefPubMedPubMedCentral

49.

Duncan JS, Kennedy HJ, Triger DR. Treatment of pruritus due to chronic obstructive liver disease. Br J Med. 1984;289:22.CrossRef

50.

Glantz A, Rielly SJ, Benthin L, Lammert F, Mattsson L, Marschall HU. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulfates in urine. Hepatology. 2008;47:544–51.CrossRefPubMed

51.

Bacq Y, le Besco M, Lecuyer AI, Gendrot C, Potin J, Andres CR, et al. Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: results in real-world conditions and factors predictive of response to treatment. Dig Liver Dis. 2017;49(1):63–9. https://doi.org/10.1016/j.dld.2016.10.006.CrossRefPubMed

52.

• Grand’Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can. 2014;36(7):632–41. https://doi.org/10.1016/s1701-2163(15)30544-2. A meta-analysis of 11 randomized controlled trials examining the safety and effectiveness of UDCA for the treatment of intrahepatic cholestasis of pregnancy. CrossRefPubMed

53.

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308. https://doi.org/10.1002/hep.22906.CrossRefPubMed

54.

•• European Assocaition for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cirrhosis. J Hepatol. 2017;67:145–72. Recently updated guidelines from the European Association for the Study of the Liver on the management of PBC. CrossRef

55.

Scaldaferri F, Pizzoferrato M, Ponziani FR, Gasbarrini G, Gasbarrini A. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med. 2013;8:205–10.CrossRefPubMed

56.

Kuiper EM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(4):1334–40. https://doi.org/10.1002/hep.23821.CrossRefPubMed

57.

Hilal-Dandan R, Brunton LL. Goodman and Gilman’s manual of pharmacology and therapeutics, Second Edition. China: The McGraw-Hill Companies, Inc; 2014.

58.

Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26(8):943–8. https://doi.org/10.1111/j.1478-3231.2006.01326.x.CrossRefPubMed

59.

Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev. 2016;11:CD008320. https://doi.org/10.1002/14651858.CD008320.pub3. PubMed

60.

Li T, Chiang TYL. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol. 2005;288(1):G74–84.CrossRefPubMed

61.

Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436–9.CrossRefPubMedPubMedCentral

62.

Martinez E, Collazos J, Myo J. Hypersensitivity reactions to rifampin: pathogenetic mechanisms, clinical manifestations, management strategies, and review of anaphylactic-like reactions. Medicine (Baltimore). 1999;78:361–9.CrossRef

63.

Bergasa NV, Alling DW, Talbot T, Swain MG, Yurdaydin C, Turner M, et al. Effects of naloxone infusions in patients with pruritus of cholestasis. Ann Intern Med. 1995;123:161–7.CrossRefPubMed

64.

Wolfhagen FKJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, Van Buuren H. Oral naltrexone for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113:1264–9.CrossRefPubMed

65.

Kumar N, Garg N, Bailey A. Opiate receptor antagonists for treatment of severe pruritus associated with advanced cholestatic liver disease. J Palliat Med. 2013;16:122–3.CrossRefPubMed

66.

Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666–74. https://doi.org/10.1002/hep.21553.CrossRefPubMed

67.

Thebaut A, Habes D, Gottrand F, Rivet C, Cohen J, Debray D, et al. Sertraline as an additional treatment for Cholestatic pruritus in children. J Pediatr Gastroenterol Nutr. 2017;64(3):431–5. https://doi.org/10.1097/MPG.0000000000001385.CrossRefPubMed

68.

Zylicz Z, Krajnik M, van Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized controlled trial. J Pain Symptom Manag. 2003;26(6):1105–12.CrossRef

69.

Antidepressants FRA. Black-box warning—10 years later. N Engl J Med. 2014;371(18):1666–8. https://doi.org/10.1056/NEJMp1410540. CrossRef

70.

Dillon S, Tobias JD. Ondansetron to treat pruritus due to cholestatic jaundice. J Pediatr Pharmacol Ther. 2013;18:241–6.PubMedPubMedCentral

71.

Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med. 1994;330:1540. https://doi.org/10.1056/NEJM199405263302117.CrossRefPubMed

72.

To TH, Clark K, Lam L, Shelby-James T, Currow DC. The role of ondansetron in the management of cholestatic or uremic pruritus—a systematic review. J Pain Symptom Manag. 2012;44(5):725–30. https://doi.org/10.1016/j.jpainsymman.2011.11.007.CrossRef

73.

European Association for the Study of the L. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67. https://doi.org/10.1016/j.jhep.2009.04.009.CrossRef

74.

Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011;1:CD003626. https://doi.org/10.1002/14651858.CD003626.pub2.

75.

Poupon R, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of Ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1549–54.CrossRef

76.

Jorgensen R, Angulo P, Dickson R, Lindor K. Results of long-term ursodiol for treatment of patients with primary biliary cirrhosis. Am J Gastroenterol. 2002;97(97):2647–50.CrossRefPubMed

77.

Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther. 2015;9:5407–19. https://doi.org/10.2147/DDDT.S92041.PubMedPubMedCentral

78.

Bolier R, de Vries ES, Pares A, Helder J, Kemper EM, Zwinderman K, et al. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. 2017;18(1):230. https://doi.org/10.1186/s13063-017-1966-8. CrossRefPubMedPubMedCentral

79.

Metreau JM, Bismuth H, Franco D, Dhumeaux D. Effect of phenobarbital in a case of extrahepatic cholestasis. Gastroenterology. 1975;68:567–71.PubMed

80.

Shneider BL, Morris A, Vockley J. Possible phenylacetate hepatotoxicity during 4-phenylbutyrate therapy of Byler disease. J Pediatr Gastroenterol Nutr. 2016;62(3):424–8. https://doi.org/10.1097/MPG.0000000000001082.CrossRefPubMed

81.

Simons FER, Watson WTA, Chen XY, Minuk GY, Simons KJ. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol. 1989;29:809–915.CrossRefPubMed

82.

Simons FER, Watson WTA, Minuk GY, Simons KJ. Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. J Clin Pharmacol. 1993;33:949–54.CrossRefPubMed

83.

Pares A, Herrera M, Aviles J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;53(2):307–12. https://doi.org/10.1016/j.jhep.2010.02.031.CrossRefPubMed

84.

Oldakowska-Jedynak U, Jankowska I, Hartleb M, Jirsa M, Pawlowska J, Czubkowski P, et al. Treatment of pruritus with Prometheus dialysis and absorption system in a patient with benign recurrent intrahepatic cholestasis. Hepatol Res. 2014;44(10):E304–E8. https://doi.org/10.1111/hepr.12262. CrossRefPubMed

85.

Tsipotis E, Shuja A, Jaber BL. Albumin dialysis for liver failure: a systematic review. Adv Chronic Kidney Dis. 2015;22(5):382–90. https://doi.org/10.1053/j.ackd.2015.05.004. CrossRefPubMed

86.

Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the AASLD and the American Society of Transplantation. Hepatology. 2014;59(3):1144–65.CrossRefPubMed

87.

Khungar V, Goldberg DS. Liver transplantation for Cholestatic liver diseases in adults. Clin Liver Dis. 2016;20(1):191–203. https://doi.org/10.1016/j.cld.2015.08.011.CrossRefPubMed

88.

•• Hegade VS, Kendrick SFW, Dobbins RL, Miller SR, Thompson D, Richards D, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114–23. https://doi.org/10.1016/s0140-6736(17)30319-7. A phase 2 study of a novel ileal bile acid transporter inhibitor, GSK2330672, that demonstrated effectiveness in the treatment of cholestatic pruritus. CrossRefPubMed

89.

•• Mayo MJ, Pockros P, Jones D, Bowlus C, Levy C, Patanwala I, et al. Clarity: a phase 2, randomized, double-blind, placebo-controlled study of lopixibat chloride (formerly Lum001), a novel apical sodium-dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching. J Hepatol. 2016;64(2):S197. https://doi.org/10.1016/s0168-8278(16)00146-x. A phase 2 study of a different novel ileal bile acid transporter inhibitor, lopixibat (now maralixibat) that showed improvement in cholestatic pruritus though was not statistically significant. CrossRef

90.

•• Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47:972–82. A phase 3 trial of a novel κ-opioid recent agonist, nalfurafine hydrochloride, demonstrating effectiveness in the treatment of cholestasis pruritus. CrossRefPubMed

Titel: Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures
verfasst von: Mark Pederson
Marlyn J. Mayo
Publikationsdatum: 06.04.2018
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 2/2018
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0397-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Treatment of DAA-Experienced Patients with Chronic Hepatitis C

Strategies for the Elimination of Hepatitis C Virus Infection as a Public Health Threat in the United States

The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development

Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations

Ethnic and Racial Differences in Autoimmune Liver Diseases